Tratamiento con palopegteriparatida para el hipoparatiroidismo en la poliendocrinopatía autoinmune-candidiasis-distrofia ectodérmica: una serie de casos y actualización de la literatura

palopegteriparatide and were followed over the subsequent 4-15 mo period. We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration. These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements © The Author(s) 2026. Published by Oxford University Press on behalf of the